Journavx

Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study

A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing development of the oral drug in diabetic peripheral neuropathy.

By Frank Vinluan

BioPharma, Pharma

Journavx suzetrigine Vertex Pharmaceuticals

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a key pathway in the peripheral nervous system.

By Frank Vinluan